A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00963313 |
Recruitment Status :
Completed
First Posted : August 21, 2009
Last Update Posted : September 23, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Psoriatic Arthritis | Drug: Adalimumab (HUMIRA®) |
A recent review from GRAPPA group evaluates therapies for PsA including peripheral and axPsA. Analysing particularly the results with present biologic therapies it has been proven that outcome data at 24 weeks show excellent results in the treatment of peripheral forms of PsA with either of the three biologics disposable in the market, that is to say infliximab, etanercept and adalimumab.
However when it comes to analyse data on PsA patients with axPsA there are not results at all. The design of clinical trials did not evaluate axial outcomes and therefore there is not a possibility of knowing whether these therapies are useful in axPsA.
This is an open label multicenter study designed to evaluate the effectivity of adalimumab 40 mg every 2 weeks during 24 weeks in patients with active axial PsA despite receiving Methotrexate, Sulfasalazine, Leflunomide or Cyclosporine, plus NSAIDs and no more than 10 mg of corticosteroids.
Study Type : | Observational |
Actual Enrollment : | 29 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis |
Study Start Date : | March 2010 |
Actual Primary Completion Date : | June 2012 |
Actual Study Completion Date : | June 2014 |

Group/Cohort | Intervention/treatment |
---|---|
Adalimumab, injection
Adalimumab, one injection every fourteen days during 24 weeks.
|
Drug: Adalimumab (HUMIRA®)
Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
Other Name: HUMIRA® |
- BASDAI score (Bath Ankylosing Spondylitis Disease Activity Index). [ Time Frame: 12 WEEKS ]Proportion of patients that reach a BASDAI 50% at week 12, BASDAI 50% means an improvement from baseline of 50% or an improvement of two units on a 10 unit scale.
- Number of participants with new adverse events. [ Time Frame: 24 WEEKS ]
- ASAS 40 score. [ Time Frame: 24 WEEKS ]
- ASAS 50 and ASAS 70 score, 5/6. [ Time Frame: 12 WEEKS ]
- Evaluation of enthesitis. [ Time Frame: 24 WEEKS ]
- Peripheral articulation measured with DAS 28. [ Time Frame: 24 WEEKS ]
- Evaluation of extraarticular manifestations. [ Time Frame: 24 WEEKS ]
- Measure of laboratory parameters. [ Time Frame: 24 WEEKS ]Hematology, biochemistry, CRP, ESR, HLA-B27 and rheumatoid factor.
- Evaluation of quality of life. [ Time Frame: 24 WEEKS ]SF36
- Measure of PASI (Psoriasis Area and Severity Index). [ Time Frame: 24 WEEKS ]
- Measure of Modified NAPSI (Modified Nail Psoriasis Severity Index). [ Time Frame: 24 WEEKS ]
- Measure of BASFI (Bath Ankylosing Spondylitis Functioning Index). [ Time Frame: 24 WEEKS ]
- Evaluation of health. [ Time Frame: 24 WEEKS ]HAQ (Health Assessment Questionarie).
- Evaluation of dactylitis. [ Time Frame: 24 WEEKS ]
- Measure of inflammatory biomarkers (IL6 and MMP3). [ Time Frame: 24 WEEKS ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Males and females aged between 18 and 70 years.
- A negative pregnancy test for women of childbearing potential during the screening period.
- Subject must be evaluated for active or latent TB (tuberculosis) infection by using a PPD skin test (Mantoux test), Booster test, chest x-ray and detailed review of subjetc´s medical history.
- Subjects to whom the doctor has decided to prescribe adalimumab, because of fulfilling the requirements for this treatment.
- Diagnosed with PsA according to CASPAR criteria.
- Axial disease according to radiological criteria (at least unilateral sacroilitis grade II) and spinal inflammatory symptoms.
- Disease duration of no less than 24 weeks
- Patients with peripheral involvement (mixed forms of APs) must have been taking MTX for at least 12 weeks before screening and at stable doses of 10 to 25 mg/week for 8 weeks before screening, or salazopyrine up to 3 mg/daily, or cyclosporin 2mg/kg or leflunomide 20 mg daily in the same conditions as MTX.
- Patient's doses of NSAIDs and oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) should have been kept stable for 4 weeks before screening.
Exclusion Criteria:
- Contraindications for treatment with anti-TNF.
- Prior treatment with other TNF inhibitors or other investigational drugs during the last 30 days (etanercept 4 weeks, infliximab 8 weeks).
- Uncontrolled diabetes.
- Uncontrolled high blood pressure.
- Unstable ischemic heart disease.
- Congestive heart failure.
- Severe pulmonary disease.
- Chronic leg ulcer.
- History of cancer or malignant lymphoproliferative disease.
- Positive serology for Hepatitis B indicating active infection or positive serology for Hepatitis C.
- History of positive HIV status.
- Persistent, recurrent or severe infections requiring hospitalization or treatment with oral antibiotics within 14 days prior to enrollment.
- Previous diagnosis or signs highly indicative of central nervous system demyelinating diseases.
- Active tuberculosis, histoplasmosis or listeriosis.
- History or presence of confirmed blood dyscrasia.
- Female subjects who are pregnant or breast-feeding.
- History of clinically significant drug or alcohol abuse in the last year.
- Treatment with MTX, salazopyrine, ciclosporin or leflunomide initiated within the last 4 weeks before the screening. Treatment with corticosteroids (>10mg/day or equivalent or modified dose within the previous 4 weeks before screening). And patients where an intraarticular corticoid infiltration has been practised within the last 4 weeks before the screening will be excluded from the study.
- Treatment with more than one NSAID within the last 4 weeks before the screening.
- Patients treated with any DMARD different from MTX, cyclosporine, leflunomide and sulfasalazine.
- Dosage of concomitant MTX, cyclosporine, leflunomide and sulfasalazine must be stable during the study, otherwise it should be properly justified and recorded in the case report form.
- Patients treated with any analgesic different from acetominophen, NSAIDs, oxycodone, codeine, propoxyphene, tramadol, hydrocodone or combinations of these products or equivalents. The use of potent opioids is not permitted.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00963313

Study Chair: | Francisco J. Blanco-Garcia, MD, PhD | Complejo Hospitalario Universitario A Coruna |
Responsible Party: | Dr. FRANCISCO J. BLANCO-GARCIA, MD, PhD, Instituto de Investigacion Biomedica de A Coruna |
ClinicalTrials.gov Identifier: | NCT00963313 |
Other Study ID Numbers: |
SUE-ADA-2009-01 |
First Posted: | August 21, 2009 Key Record Dates |
Last Update Posted: | September 23, 2014 |
Last Verified: | September 2014 |
Axial psoriatic arthritis Adalimumab Humira anti-TNF |
Arthritis Arthritis, Psoriatic Joint Diseases Musculoskeletal Diseases Spondylarthropathies Spondylarthritis Spondylitis Spinal Diseases |
Bone Diseases Psoriasis Skin Diseases, Papulosquamous Skin Diseases Adalimumab Anti-Inflammatory Agents Antirheumatic Agents |